MAPK1 and non-small cell lung carcinoma: Cai et al. first found that NNT-AS1 was significantly up-regulated in drug-resistant tissues and cells of NSCLC, and when down-regulating NNT-AS1, the levels of p-MAPK1 and Slug in cisplatin-resistant cancer cells were significantly reduced, suggesting that NNT-AS1 may induce cisplatin resistance through the MAPK/Slug signaling pathway in NSCLC [18].